Navigation Links
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
Date:12/4/2009

BETHESDA, Md., Dec. 4 /PRNewswire/ -- Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment. Prostate cancer patients who received FIRMAGON 240/80 mg/month had a recurrence rate of 7.7% during the first year of treatment compared with 12.9% of patients treated with leuprolide 7.5 mg/month (p=0.05). Patients being treated with FIRMAGON also had longer time to recurrence compared with those on leuprolide (p=0.04).

Results of the PSA analysis were presented in a poster at the 10th Annual Meeting of the Society of Urologic Oncology, held in conjunction with the World Urological Oncology Federation, on December 3 in Bethesda, MD.

About the Study

In the Phase III multicenter, randomized, open-label trial comparing degarelix with leuprolide, prostate cancer patients (n=610) were randomized to a starting dose of degarelix 240 mg for one month, followed by monthly maintenance doses of 80 mg (n=207) or 160 mg (n=202), or leuprolide 7.5 mg/month (n=201). Results showed that degarelix is as effective as leuprolide in reducing and sustaining castrate levels of testosterone.(1),(2) Suppression of testosterone to castrate levels occurred significantly faster in patients receiving degarelix than in those receiving leuprolide.(1),(2) The study also showed that degarelix achieves faster suppression of luteinizing hormone and follicle-stimulating hormone.(1),(2)

PSA recurrence was defined as two consecutive increases in PSA of 50% compared with nadir and greater than or equal to 5 ng/mL on two consecutive measurements at least two weeks apart. PSA progression-free survival was analyzed using the Kaplan-Meier method and
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
2. BSGI Makes Significant Impact on Detection of Breast Cancer in Patients with Negative Mammographic Findings
3. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
4. Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients
5. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
6. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
7. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
8. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
9. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
10. New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
11. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician ... deliver doctors the survival tools they need to provide ... in today,s health care marketplace. "I am ... save local practices," said Stephen L. Brotherton ... (TMA). " Texas doctors are determined ...
(Date:5/23/2013)... , May 23, 2013   Direct ... following mastectomy is an appropriate option for many ... to surgically reduce their breast cancer risk, or ... gradual expansion process and a second surgery to ... in the same surgery as mastectomy can be ...
(Date:5/23/2013)... 2013  BioElectronics Corporation (OTC Pink: BIEL), the maker ... the FDA panel meeting for non-thermal shortwave diathermy: ... Shortwave Therapy Meeting was held on May 21, 2013 ... focus of the meeting was very narrow, in that ... on the application of non-thermal shortwave diathermy for the ...
Breaking Medicine Technology:TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Inc. (the "Company") (NASDAQ and MTA: CTIC) today announced ... a reverse stock split following the Company,s receipt on ... the staff of The NASDAQ Stock Market LLC (the "NASDAQ"). ... compliance with NASDAQ Listing Rule 5550(a)(2) because the Company,s ...
... 5, 2011 Cardiac Network, Inc. (Other OTC: CNWI.PK) (the ... reverse stock split (the "Reverse Stock Split"). The Reverse Stock ... trading on May 6, 2011 (the "Effective Date"). On the ... "CNWI" to "CNWID" for approximately 20 business days, after which ...
Cached Medicine Technology:Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing 2Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing 3Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing 4Cardiac Network Announces Reverse Stock Split 2
(Date:5/25/2013)... Pradaxa lawsuits filed on behalf ... bleeding while using the blood thinner continue to mount in ... of Illinois, Bernstein Liebhard LLP reports. According to a ... had been filed in the litigation as of ... by the Court on May 15th. ( In Re: Pradaxa ...
(Date:5/25/2013)... May 25, 2013 The latest ... from irritable bowel syndrome (IBS) to bloating, constipation, ... the most long-lasting, embarrassing, frustrating and difficult health ... for digestive health have provided a cure ... many factors contributing to digestive health issues, a ...
(Date:5/25/2013)... 25, 2013 By working diligently for ... the integration of the 2012 Lamborghini Aventador into their ... latest entrant in the list of vehicles lined by ... is all set to thrill automobile lovers in the ... and spectacular looks, the 2012 Lamborghini Aventador comes with ...
(Date:5/25/2013)... On May 25, Voices Against Brain ... advocacy, comments on a new study by the Max ... atmospheric plasma into brain cancer treatment may help when ... Science Daily article, physicists from the Max ... demonstrated the “synergistic effect of cold atmospheric plasma -- ...
(Date:5/25/2013)... According to a new market report,"Global ... by MarketsandMarkets is expected to reach $544.02 Billion ... analyzes and studies the major market drivers, restraints, ... Rest of the World. , Browse:, ... 87 Figures , 175 Pages ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
... scientists from Bristol University has developed a technique, using luciferase, ... aid in detecting// damage to heart cells after a heart ... way for rapid recovery from cardiac arrests and heart surgery. ... Journal of Biological Chemistry. ,Dr Elinor Griffiths and ...
... to enable manifold benefits for patients, but health ... before such drugs are recommended for their patients, ... (GI) morbidities are becoming common fallouts of NSAID ... upper- and lower-GI tracts; this may include even ...
... identify biomarker combinations associated with mortality among people.,Previous ... that can predict disability, morbidity and mortality in ... researchers analyzed 13 biomarkers representing neuroendocrine and vascular ... years in 1,189 high-functioning men and women aged ...
... become the first hospital in the region to ... doctors believe will change the standard of care ... OR/Cath Lab, the state-of-the-art operating suite houses all ... open-heart surgeries, like coronary bypass, as well as ...
... former drug addict from Manipur has set up a support ... the dying and to rescue the perishing".// ,K. Gouchinkhup, ... said: "A sense of curiosity and peer pressure led me ... ,"Since then I have taken heroin, pharmaceutical drug ...
... first large, single-institution series directly comparing weight-loss outcomes ... Chicago found that a newer operation//, the duodenal ... standard operation, the Roux-en-Y gastric bypass. ,In ... the researchers report that the duodenal switch (DS) ...
Cached Medicine News:Health News:A glowing energy measure for heart cells 2Health News:Nonsteroidal anti-inflammatory drugs could cause gastrointestinal complications. 2Health News:Nonsteroidal anti-inflammatory drugs could cause gastrointestinal complications. 3Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 2Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 3Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 4Health News:Ex-drug Addict has set up Support System for Drug Victims 2Health News:For Super-Obese Patients, Duodenal Switch Beats Gastric Bypass 2Health News:For Super-Obese Patients, Duodenal Switch Beats Gastric Bypass 3
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ENDO ... three (3) atraumatic fingers, ... variety of gynecologic, general, ... procedures for temporary retraction ...
... The Auto Suture™ ENDO PADDLE RETRACT™ ... variety of gynecologic, general, urologic,thoracic, colorectal and ... e.g., the bowel, stomach, or liver. , ... of a paddle retractor at the distal ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
Medicine Products: